Abstract
Interferon-regulated antiviral (IRAV) gene is a novel interferon-stimulated gene (ISG) with known antiviral activity in humans, yet its role in porcine immunity has remained largely uncharacterized. In this study, researchers successfully cloned the full-length porcine IRAV cDNA (1241 bp) from kidney cells, encoding a 285-amino acid protein that localizes to the cytoplasm. Following expression in Escherichia coli, the recombinant protein was used to generate five specific monoclonal antibodies (MAbs): 2B10, 2G12, 2H1, 5A8, and 2C5. These tools, validated via Western blot and immunofluorescence, provide a critical foundation for investigating the biological function of IRAV in protecting swine against major viral pathogens.
Introduction
The global swine industry faces significant economic threats from viral pathogens such as Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and African Swine Fever Virus (ASFV). Understanding the innate immune response is vital for developing effective interventions. When cells detect viral invasion, they release interferons (IFNs), which trigger the expression of hundreds of Interferon-Stimulated Genes (ISGs). While IRAV has been identified as a potent antiviral factor against viruses like Dengue in humans, the lack of porcine-specific genetic data and detection tools has hindered research into its role in pigs. This study aims to bridge that gap by characterizing porcine IRAV and developing high-affinity monoclonal antibodies.
Methods
The researchers utilized a comprehensive molecular biology approach to characterize the gene and its product:
- Cloning and Sequencing: RNA was isolated from porcine spleen tissue. RT-PCR and Rapid Amplification of cDNA Ends (RACE) were employed to determine the complete 1241 bp sequence of the porcine IRAV gene.
- Bioinformatics: The sequence was compared across various species to establish phylogenetic relationships and predict protein structure.
- Protein Expression: The gene was expressed in E. coli BL21 (DE3) to produce recombinant protein (rpIRAV) for immunization. Additionally, it was expressed in porcine kidney (PK-15) cells with a FLAG-tag for localization studies.
- Monoclonal Antibody Production: Purified rpIRAV was used to immunize female BALB/c mice. Hybridoma technology was used to create cell lines secreting specific anti-IRAV MAbs.
- Validation: The specificity of the MAbs was confirmed using Western blot analysis and Indirect Immunofluorescence Assays (IFA) to visualize the protein in situ.
Results
Sequence and Evolutionary Analysis
The porcine IRAV cDNA was found to be 1241 bp long, containing an open reading frame (ORF) of 858 bp that encodes a 285-amino acid polypeptide. Interestingly, phylogenetic analysis revealed that porcine IRAV shares its highest amino acid identity (96.2%) with the whale version of the gene, clustering closely with other cetaceans and hoofed mammals (bovine and sheep) rather than rodents or humans.
Cellular Localization and Protein Expression
Confocal microscopy of FLAG-tagged porcine IRAV in PK-15 cells confirmed that the protein localizes predominantly within the cytoplasm. This localization is strategic, as the cytoplasm is the primary battlefield where many RNA viruses replicate. The recombinant protein migrated at approximately 35 kDa on SDS-PAGE, aligning with the predicted molecular weight.
Antibody Specificity
Five hybridoma strains (2B10, 2G12, 2H1, 5A8, and 2C5) were successfully established. Validation through Western blot and IFA demonstrated that these MAbs specifically recognize the overexpressed porcine IRAV protein with minimal background noise, confirming their utility as high-precision research tools.
Discussion and Conclusion
This study provides the essential molecular "toolkit" for studying the porcine innate immune system. By defining the genetic sequence and producing specific monoclonal antibodies, the researchers have enabled future functional studies to determine how IRAV inhibits specific swine viruses.
While the current work establishes the presence and localization of the protein, further research is required to elucidate the exact mechanism of action—whether IRAV interferes with viral entry, protein synthesis, or genome replication. Ultimately, these findings could inform the development of transgenic pigs with enhanced natural resistance to devastating diseases, offering a sustainable solution for the swine industry.
Summary updated